A Randomized, Double-blind, Placebo-controlled, 4-way Crossover Study to Compare the Effects on the Cardiac De- and Repolarization Duration as Well as Other Cardiac Safety Parameters of Two Doses of Oral Lasmiditan (100 mg and 400 mg) With Those of Moxifloxacin (400 mg) and Placebo in Healthy Subjects
Latest Information Update: 01 Feb 2020
At a glance
- Drugs Lasmiditan (Primary) ; Moxifloxacin
- Indications Migraine
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 24 Sep 2012 New trial record